Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXN110527: XP13512 in post-herpetic neuralgia patients with inadequate response to gabapentin
2008-004933-99Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gabapentin enacarbil in postherpetic neuralgia (PHN) and Neuralgia (2 arms), sponsored by GSK. Primary endpoint: Mean 24-hour average pain intensity score (PI-NRS) in last treatment week of each period. Started Sep 2008; status: completed.
02
Drugs
gabapentin enacarbil
03
Conditions
postherpetic neuralgia (PHN)Neuralgia
Beyond the preview
Go deeper on 2008-004933-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004933-99.